Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chris Pappas

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinics in Liver Disease|November 21, 2018
Alcohol and the LawMaya Balakrishnan, Stephen Chris Pappas
Journal of Experimental Pharmacology|January 6, 2018
In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V<sub>1</sub> and V<sub>2</sub>Khurram Jamil, Stephen Chris Pappas, Krishna R Devarakonda
Alimentary Pharmacology & Therapeutics|August 22, 2022
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failureFlorence Wong, Stephen Chris Pappas, K Rajender Reddy, et al.
Alimentary Pharmacology & Therapeutics|July 24, 2025
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical StudiesJasmohan S Bajaj, Paul Kwo, Stephen Chris Pappas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2016
Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response SyndromeFlorence Wong, Stephen Chris Pappas, Thomas D Boyer, et al.
Gastroenterology|February 21, 2016
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1Thomas D Boyer, Arun J Sanyal, Florence Wong, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinics in Liver Disease|November 21, 2018
Alcohol and the LawMaya Balakrishnan, Stephen Chris Pappas
Journal of Experimental Pharmacology|January 6, 2018
In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V<sub>1</sub> and V<sub>2</sub>Khurram Jamil, Stephen Chris Pappas, Krishna R Devarakonda
Alimentary Pharmacology & Therapeutics|August 22, 2022
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failureFlorence Wong, Stephen Chris Pappas, K Rajender Reddy, et al.
Alimentary Pharmacology & Therapeutics|July 24, 2025
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical StudiesJasmohan S Bajaj, Paul Kwo, Stephen Chris Pappas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2016
Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response SyndromeFlorence Wong, Stephen Chris Pappas, Thomas D Boyer, et al.
Gastroenterology|February 21, 2016
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1Thomas D Boyer, Arun J Sanyal, Florence Wong, et al.
Pageof 1